ADC Therapeutics SA (ADCT)vsargenx NV ADR (ARGX)
ADCT
ADC Therapeutics SA
$1.03
-21.97%
HEALTHCARE · Cap: $432.45M
ARGX
argenx NV ADR
$891.32
+5.82%
HEALTHCARE · Cap: $55.09B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 5890% more annual revenue ($4.74B vs $79.17M). ARGX leads profitability with a 31.4% profit margin vs -173.0%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ADCT
Avoid22
out of 100
Grade: F
ARGX
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ADCT.
Margin of Safety
+62.4%
Fair Value
$2217.64
Current Price
$891.32
$1326.32 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 30.0%
Revenue surging 62.6% year-over-year
Earnings expanding 114.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -706.0% — below average capital efficiency
Revenue declined 9.5%
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 188.4x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ADCT
The strongest argument for ADCT centers on Debt/Equity.
Bull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 31.4% and operating margin at 30.0%. Revenue growth of 62.6% demonstrates continued momentum.
Bear Case : ADCT
The primary concerns for ADCT are EPS Growth, Market Cap, Return on Equity.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Key Dynamics to Monitor
ADCT profiles as a turnaround stock while ARGX is a growth play — different risk/reward profiles.
ADCT carries more volatility with a beta of 1.84 — expect wider price swings.
ARGX is growing revenue faster at 62.6% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (73/100 vs 22/100), backed by strong 31.4% margins and 62.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ADC Therapeutics SA
HEALTHCARE · BIOTECHNOLOGY · USA
ADC Therapeutics SA, a biotechnology company focused on clinical stage oncology, develops Antibody Drug Conjugates (ADC) for patients suffering from hematologic malignancies and solid tumors. The company is headquartered in Epalinges, Switzerland.
Visit Website →argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?